ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
PhosSight: A Unified Deep Learning Framework Boosting and Accelerating Phosphoproteome Identification to Enable Biological Discoveries.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Protein phosphorylation is a key regulator of signaling, with mass spectrometry (MS) based phosphoproteomics serving as the premier technology for its analysis. However, phosphorylation profiling is hindered by acquisition biases: Data-Dependent Acquisition (DDA) suffers from stochastic undersampling and missing values, while Data-Independent Acquisition (DIA) faces computational bottlenecks and inefficiencies from vast spectral libraries. We present PhosSight, a unified deep learning framework designed to augment identification depth and accelerate search efficiency. PhosSight features PhosDetect, a model that explicitly encodes phosphorylation-specific physicochemical features to accurately predict peptide detectability. For DDA, PhosSight leverages predicted retention time, fragment intensity, and detectability to refine site localization and rescoring, recovering marginal, low-abundance spectra. For DIA, PhosSight utilizes detectability-guided library pruning to remove non-detectable noise, accelerating search speeds without compromising sensitivity. Benchmarking on synthetic and real-world datasets confirms PhosSight's superior performance in both modes. Applying PhosSight to a large-scale Uterine Corpus Endometrial Carcinoma (UCEC) cohort improved data completeness and expanded the quantifiable phosphoproteome. This enhanced completeness enabled the discovery of novel prognosis-associated kinase targets, such as MARK2, underscoring PhosSight as a powerful tool for biological discovery in precision oncology. Trial Registration: Not applicable. This study did not prospectively assign human participants to any health-related intervention and therefore does not constitute a clinical trial requiring registration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.